" class="no-js "lang="en-US"> WELL Health - Medtech Alert
Monday, October 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
WELL Health | Pharmtech Focus

WELL Health

About WELL Health

WELL Health

WELL™ Health is upending the $3.5 trillion healthcare market by helping patients and administrators break free of antiquated communication practices. This 2021 Best in KLAS for Patient Outreach software provides medical organizations with a single command center that connects the many tools they use, transforming everyday interactions between patients and the doctor’s front office.

Related Story

Appointments

 WELL Health Adds Chief Medical Officer Sean Kelly to Leadership Team | Pharmtech Focus

WELL Health Adds Chief Medical Officer Sean Kelly to Leadership Team

November 4 2021

Well Health Inc., a SaaS digital health leader in patient communications and 2021 Best in KLAS […]